MacroGenics, Inc.
Antibodies reactive with B7-H3 and users thereof

Last updated:

Abstract:

The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

Status:
Grant
Type:

Utility

Filling date:

4 Jan 2018

Issue date:

4 Aug 2020